Moderna is studying a potential vaccine for the prevention of cytomegalovirus (also called CMV). Clinical research studies and the volunteers who take part in research studies are vital to creating vaccines that will safely protect people from all ages and backgrounds against viruses.
The purpose of this research study is to understand how the body responds to different doses of the mRNA-1647 investigational vaccine that may protect women against CMV. This study will specifically look for any side effects of the vaccine and whether or not an immune response is generated. Results from this study will be used to select the best dose of the mRNA-1647 vaccine to be used in future studies.


A Clinical Trial of a Cytomegalovirus (CMV) Vaccine in Healthy Adults

The mRNA-1273-P203 study is testing an investigational vaccine that may protect adolescents who are between the ages of 12 - 17 from getting sick if they come into contact with the SARS-COV-2 virus, which causes COVID-19; also known as coronavirus. 

A vaccine that prevents COVID-19 disease and SARS-CoV-2 transmission in adolescents would be a crucial public health tool to help curb the pandemic.

The purpose of this study is to seek an indication for use of the mRNA-1273 vaccine in adolescents of 12-17 years old. Study volunteers will participate and be followed by medical staff for a total of 13 months.


A Clinical Trial of a COVID-19 Vaccine in Adolescents (ages 12 to 18 Years)

This study is evaluating an investigational combination vaccine, called mRNA-1653, to protect against hMPV and PIV3. Both hMPV and PIV3 are known to cause respiratory disease in people of all ages, often in children.

This study will evaluate the safety and immune responses of the mRNA-1653 vaccine when administered to children ages 1 year and less than 5 years of age who have previously had an infection with both hMPV and PIV3 (this could have been just what seemed like a mild common cold).

There are no approved vaccines to prevent hMPV or PIV3 infections. A safe and effective vaccine against hMPV and PIV3 has the potential to substantially improve the health of young children.


A Clinical Trial of a Human Metapneumonovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine in Healthy Adults and Children

Researchers in the mRNA-1283-P101 study are testing if the mRNA-1283 investigational vaccine may be effective in preventing COVID-19. 

The study is enrolling individuals who are 18-55 years old and are in good health. Participants in the study will receive either the mRNA-1283 study vaccine or the mRNA-1273 vaccine. mRNA-1283 is not currently authorized for preventing COVID-19. 

A Clinical Trial of a COVID-19 Vaccine in Healthy Adults

An Observational Study of the mRNA-1273 COVID-19 Vaccine in Pregnant Women

The mRNA-1010-P101 clinical trial is evaluating if an investigational mRNA vaccine is safe and effective in preventing the flu in adults. 

Current seasonal flu vaccines are usually only 60% effective at best, and they often perform poorly during years when the circulating flu strains don’t match the strains selected for that year’s vaccine. Flu vaccines based on mRNA technology could potentially provide several benefits compared to current vaccines, including the ability to respond to changes in influenza strains more quickly, stronger immune responses, and improved protection in older adults.


A Clinical Trial of a Seasonal Flu Vaccine in Healthy Adults

A Clinical Trial of a Zika Vaccine in Healthy Adults

A Clinical Trial of a Personalized Cancer Vaccine in Patients with Solid Tumors

A Clinical Trial of a Treatment Alone and in Combination with Durvaluman in Patients with Advanced Malignancies

A Clinical Trial of a Chikungunya Vaccine in Healthy Adults

A Clinical Trial of a Human metapneumovirus (hMPV) Vaccine in Healthy Adults

A Natural History Study of Patients with Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

A Clinical Trial of a Treatment for Patients with Advanced Malignancies

A Clinical Trial of a Treatment for Patients with Methylmalonic Acidemia (MMA)

A Clinical Trial of a Personalized Cancer Vaccine in Patients with Skin Cancer

A Clinical Trial of a Treatment for Patients with Propionic Acidemia

A Clinical Trial of a Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults and Children

A Clinical Trial of an Autoimmune Therapeutic in Healthy Adults

A Clinical Trial of a Zika Vaccine in Adults

A Clinical Trial to Evaluate mRNA Investigational Vaccine Boosters for COVID-19 Variants

An Extension Study for Participants in mRNA-1647-P202

A Clinical Trial of a Treatment for Patients with Glycogen Storage Disease Type 1a (GSD1a)

A Clinical Trial of a Cytomegalovirus (CMV) Vaccine in Healthy Adults of Japanese Descent

Often vaccines for viruses are made from a weakened or inactive (not live) virus, but the mRNA-1273 study vaccine is different. It is made from an instructional molecule called mRNA that tells your cells how to make protein. In this case, the protein is a small part of the virus that is thought to help the body’s immune system protect itself if you ever come in contact with the coronavirus.

Participation in the KidCOVE Study lasts up to 17 months and includes phone calls, telemedicine visits, and up to eight visits to the study site.

- In Part 1 and 2 of the study, participants will be given two injections in the upper arm or thigh—about 28 days apart. Participants in these groups have a chance of receiving either the mRNA-1273 study vaccine or the placebo. By using a placebo, medical researchers are able to understand if the study vaccine is effective in preventing COVID-19.
- In Part 3 of the study, participants ages 6 years to < 12 years will be given three injections in the upper arm — the first two doses will be about 28 days apart, and the third dose will be given approximately 4 months after the second dose. All participants in this group will receive the mRNA-1273 investigational vaccine.
- Each part of the study may run in parallel or may close at different times, meaning eligibility may vary based on age and location.
- Participants and their caregivers will be asked to return to the study site up to seven times depending on their enrollment assignment.
- Participants and their caregivers will have two telemedicine visits with the study doctor after each injection, and then monthly after that to monitor for COVID-19 symptoms. During these phone calls, the study doctor and medical staff will check how the participant is feeling and ask for updates on their health.
- Caregivers of participants will be asked to use an eDiary app on your smartphone or a provided smartphone to report any COVID-19 symptoms the participants experience.
- Participants will be closely monitored by the study team if any symptoms of COVID-19 are reported at any time throughout their participation.

The study doctor and medical staff will talk to participants and their caregivers about additional medical support that they will receive if they experience COVID-19 symptoms at any time while in this clinical trial. Insurance is not needed to join this clinical trial, and compensation for your time will be available.


The primary purpose of the KidCOVE Study is to test the safety and effectiveness of the study vaccine, called mRNA-1273, that may protect children between the ages of 6 months to < 12 years from getting sick if they come into contact with SARS-CoV-2, which causes COVID-19. Moderna will be recruiting multiple age groups from 6 months to < 12 years and staggering the recruitment of each group. The goal of this study is to evaluate the safety and effectiveness of different dose amounts and regimens, including a three-dose regimen in children 6 to < 12 years. Please be aware that there may be a delay in hearing from a study site, or the site near you may no longer be recruiting in a specific age group.


A COVID-19 Vaccine Study for Children

Participation in the COVE Transplant Study lasts approximately 13 months and includes approximately seven visits to the study site and nine phone calls.

- Participants will have two injection visits, which will happen on Day 1 and on Day 29. 
- Participants will be asked to return to the study site seven days after each injection and then two months, seven months, and 13 months after the first injection. During these study site visits, the study team will monitor for COVID-19 symptoms.
- Participants will be contacted by the study team to monitor for COVID-19 symptoms every four weeks from Day 85 to Day 197, and again from Day 237 to Day 377. During these phone calls, the study team will check how each participant is feeling and ask for updates on their health.
- Participants will also be asked to complete daily eDiary entries for one week after each injection visit. Participants will be asked to complete monthly eDiary entries from Day 71 to Day 183 and from Day 223 to Day 363.

Insurance is not needed to join this trial and compensation for the participant’s time will be available.


Researchers in the COVE Transplant Study are trying to find solutions to the COVID-19 pandemic that can help everyone – including those who have received a kidney or liver transplant.

The purpose of this study is to evaluate an investigational vaccine that may prevent illness after exposure to SARS-CoV-2, which causes COVID-19. There will be two participant groups in this study – a group of individuals who have had a solid organ transplant and are immunocompromised from the transplant, and a control group of individuals who are in good health. The control group is included as a comparison group to help understand how immune cells act after vaccination. Both groups will receive the COVID-19 vaccine.

Unvaccinated solid organ transplant participants will have the option to receive a third dose of the COVID-19 vaccine. Vaccinated solid organ transplant participants will receive a third dose of the COVID-19 vaccine.

A Clinical Trial of a COVID-19 Vaccine in Kidney or Liver Transplant Recipients

Cytomegalovirus, shortened to CMV, is a leading cause of birth defects around the world. CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people. But if a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to suffer long-term disability due to birth defects, including hearing loss, or even death in very severe cases. Currently, there is no approved vaccine against CMV.

The total length of participation in this clinical trial is approximately 2½ years (30 months).

During the first 7 months, trial participants will attend 6 in-person visits, including 1 screening visit and 3 vaccination visits when they’ll receive injections in the upper arm. Each participant has a 50% chance of receiving the investigational vaccine and a 50% chance of receiving a placebo—like flipping a coin.

During the follow-up portion of the trial (Month 8 through Month 30), participants will have in-person visits every 3 months and will provide updates via an eDiary, may be contacted by telephone, or may be requested to come in for unscheduled visits in between such visits.
Participants will be closely monitored by the clinic team for any side effects. Insurance is not needed to join this trial and compensation for the participant’s time will be available.


The CMVictory Trial is studying mRNA-1647, an investigational vaccine, to understand whether it can help your immune system protect against cytomegalovirus (CMV).

The purpose of this clinical trial is to evaluate the safety and efficacy of mRNA-1647 investigational vaccine against CMV and evaluate the safety of the mRNA-1647 investigational vaccine in women who test positive to prior exposure to CMV. 


A Clinical Trial of a Cytomegalovirus (CMV) Vaccine in Healthy Women 16 to 40 Years of Age

mRNA technology uses messenger ribonucleic acid (mRNA), an instructional molecule that naturally occurs in the body and carries information to cells. In this case, Moderna is researching the use of mRNA to instruct the body to make the protein that is missing in people with GSD1a. 

People who are diagnosed with GSD1a lack one protein involved in the metabolism of sugar, which leads to frequent episodes of low glucose and a buildup of glycogen in the body’s cells in certain organs and tissues – especially in the liver.  

In this phase 1 clinical trial, Moderna is evaluating if a single intravenous (IV) infusion of the investigational medication, mRNA-3745, has the potential to correct the defect that causes GSD1a and restore function. If successful, mRNA-3745 would teach certain organs in the body to effectively break down glycogen, correct low blood glucose and avoid starch intake. 

The total length of participation in the Ba1ance Trial is a little over a year and includes approximately 20 total visits, with one overnight stay at a hospital and four additional visits at the hospital or trial doctor’s office. All other visits will be at the participant’s home where a home health nurse will perform the assessments needed if the participant and the trial doctor agree to home visits.

During the trial visits, participants will answer questions about health, diet, and quality of life. The trial team will also perform procedures such as blood and urine sample collections, physical exams, and electrocardiograms. As part of this trial, participants will be given a handheld continuous glucose monitor device (CGM) to wear for the first five weeks of the clinical trial. Throughout the trial, participants will need to record their daily starch intake in an electronic diary and adhere to a prescribed diet. 

Participants in this trial will receive a one-time IV infusion of mRNA-3745 via a small tube inserted into a vein in the arm.  Participants will be closely monitored by the clinic team for any side effects. 

Insurance is not needed to take part in the Ba1ance Trial. Travel stipend/reimbursement and compensation for the participant’s trial related time may be available.


The Ba1ance Trial aims to see if a new investigational medication, mRNA-3745, for people with glycogen storage disease type 1a (GSD1a) is safe and if it could potentially help correct the defect that causes GSD1a and restore function. If successful, mRNA-3745 would teach certain organs in the body to effectively break down glycogen, correct low blood glucose, and avoid starch intake.  

In this phase 1 clinical trial, mRNA-3745 will be administered as a single IV infusion via a small tube inserted into a vein in the arm.


A Glycogen Storage Disease Type 1a (GSD1a) clinical trial for adults

90% of people in the US are infected with Epstein-Barr virus (EBV) by age 35, but there are currently no approved vaccines to protect against EBV.  EBV is the most common cause of Infectious Mononucleosis, or 'mono', which can cause fever, tiredness (fatigue), sore throat, and swollen lymph nodes. It can also cause long-term fatigue and sometimes an enlarged spleen, which can limit activity and, rarely, may require hospitalization. Infection with the Epstein-Barr virus results in lifelong infection and the possibility of developing other diseases, as well. Currently, there is no approved vaccine for EBV or mono.

The total length of participation in the Eclipse Trial is 18 months and includes up to 15 clinical trial site visits, as well as 6 safety telephone calls. 

During the trial visits, participants will answer questions about health, diet, and
quality of life. The trial team will also perform physical exams and blood sample collection. Throughout the trial, participants will use an electronic diary (eDiary) to record any symptoms they might experience after their injection.  During the phone call appointments, the trial team will check how the participant is feeling and ask for updates on their health. 

Participants will be given three injections in the upper arm. Participants have a chance of receiving either the mRNA-1189 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against mono. Participants will be closely monitored by the clinic team for any side effects. 

Insurance is not needed to take part in the Eclipse Trial. Compensation for the participant’s trial-related time may be available.


The Eclipse Trial is evaluating the safety and immune response of an investigational vaccine, called mRNA-1189, that may protect against infectious mononucleosis (also known as mono). Participation in the Eclipse Trial lasts approximately 18 months, including a 28-day screening period, a six-month dosing period, and up to 11 months of follow-up observation.	

An Epstein-Barr Virus (EBV) vaccine clinical trial

Respiratory syncytial virus (RSV) can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia, especially in children and older adults. Currently, there is not an approved vaccine for RSV.

For pediatric participants, the total length of participation in this RSV clinical trial lasts approximately 16 months and includes up to 11 clinical trial site visits. 

Pediatric participants will be given 3 injections in the upper arm. Each participant has a chance of receiving either the mRNA-1345 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against RSV. Participants will be closely monitored by the clinic team for any side effects. 

Pediatric participants will have a mix of in-person and phone visits with the trial doctor to monitor for any symptoms after injections. During these visits and phone calls, the clinical trial doctor and medical staff will check how the participant is feeling and ask for updates on their health.

Parents or caregivers of each pediatric participant will be asked to use an eDiary app on their smartphone or a smartphone will be provided to report any symptoms the participant might experience for 7 days after the injection. 
Insurance is not needed to take part in this clinical trial. Compensation for the participant’s trial-related time may be available.


The mRNA-1345-P101 clinical trial is evaluating the safety and immune response of an investigational vaccine, called mRNA-1345, to protect against Respiratory Syncytial Virus (RSV). 

RSV can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold, and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia especially in children and older adults. Currently there is not an approved vaccine for RSV. 